Loading
The antibody-drug conjugate mirvetuximab soravtansine lengthened survival compared with chemotherapy in platinum-resistant ovarian cancer with high folate receptor alpha expression, the first drug ever to do so in this setting.
Phase 3 trial of 453 patients with platinum-resistant high-grade serous ovarian cancer, folate receptor alpha-high tumours and one to three prior regimens, randomised to mirvetuximab soravtansine or investigator's choice chemotherapy (paclitaxel, pegylated liposomal doxorubicin or topotecan).
Median progression-free survival was 5.62 versus 3.98 months (hazard ratio 0.65), objective response 42.3 versus 15.9 percent and median overall survival 16.46 versus 12.75 months (hazard ratio 0.67); ocular toxicity was frequent but mostly low grade.
Folate receptor alpha testing is now standard in platinum-resistant ovarian cancer and mirvetuximab is the preferred treatment for high-expressing tumours, with an eye-care protocol.
Shares Mirvetuximab soravtansine, High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares Mirvetuximab soravtansine, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares Mirvetuximab soravtansine, High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer.
Shares Sequence folate-receptor ADCs by payload class, Platinum-resistant ovarian cancer.